Review
doi: 10.1093/annonc/mdq194.
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Affiliations
- PMID: 20555089
- DOI: 10.1093/annonc/mdq194
Item in Clipboard
Review
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Ann Oncol.
2010 May.
Free article
No abstract available
Similar articles
-
Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: guideline update and results of the Perugia consensus conference.Support Care Cancer. 2011 Mar;19 Suppl 1:S63-5. doi: 10.1007/s00520-010-1044-1. Epub 2010 Dec 28. Support Care Cancer. 2011. PMID: 21188425 No abstract available.
-
Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).Support Care Cancer. 2011 Mar;19 Suppl 1:S57-62. doi: 10.1007/s00520-010-1039-y. Epub 2010 Dec 5. Support Care Cancer. 2011. PMID: 21132332
-
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11. ESMO Open. 2024. PMID: 38458657 Free PMC article.
-
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.Support Care Cancer. 2017 Jan;25(1):303-308. doi: 10.1007/s00520-016-3449-y. Epub 2016 Nov 4. Support Care Cancer. 2017. PMID: 27815710
-
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.Support Care Cancer. 2023 Dec 19;32(1):37. doi: 10.1007/s00520-023-08223-2. Support Care Cancer. 2023. PMID: 38110581
Cited by
-
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.Br J Cancer. 2013 Aug 20;109(4):859-65. doi: 10.1038/bjc.2013.400. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860530 Free PMC article. Clinical Trial.
-
Stress sensing within the breast tumor microenvironment: how glucocorticoid receptors live in the moment.Essays Biochem. 2021 Dec 17;65(6):971-983. doi: 10.1042/EBC20200165. Essays Biochem. 2021. PMID: 34132331 Free PMC article. Review.
-
Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.BMC Cancer. 2019 Nov 8;19(1):1066. doi: 10.1186/s12885-019-6233-9. BMC Cancer. 2019. PMID: 31703649 Free PMC article.
-
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).Support Care Cancer. 2014 Feb;22(2):469-77. doi: 10.1007/s00520-013-1999-9. Epub 2013 Oct 19. Support Care Cancer. 2014. PMID: 24141698 Free PMC article. Clinical Trial.
-
Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.Support Care Cancer. 2013 Dec;21(12):3425-31. doi: 10.1007/s00520-013-1926-0. Epub 2013 Aug 15. Support Care Cancer. 2013. PMID: 23949739 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
